Chung Wu Investment Group LLC Acquires New Holdings in Natera, Inc. $NTRA

Chung Wu Investment Group LLC acquired a new position in Natera, Inc. (NASDAQ:NTRA) during the 2nd quarter, HoldingsChannel.com reports. The firm acquired 1,000 shares of the medical research company’s stock, valued at approximately $169,000.

A number of other hedge funds have also recently made changes to their positions in NTRA. Guided Capital Wealth Management LLC lifted its stake in Natera by 0.5% during the second quarter. Guided Capital Wealth Management LLC now owns 13,135 shares of the medical research company’s stock worth $2,219,000 after purchasing an additional 66 shares in the last quarter. Wedmont Private Capital raised its holdings in shares of Natera by 4.9% in the 2nd quarter. Wedmont Private Capital now owns 1,580 shares of the medical research company’s stock valued at $256,000 after buying an additional 74 shares during the period. Compound Planning Inc. raised its holdings in shares of Natera by 4.2% in the 1st quarter. Compound Planning Inc. now owns 1,914 shares of the medical research company’s stock valued at $271,000 after buying an additional 78 shares during the period. QRG Capital Management Inc. lifted its stake in Natera by 1.5% during the 1st quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company’s stock worth $766,000 after acquiring an additional 81 shares in the last quarter. Finally, Earned Wealth Advisors LLC boosted its holdings in Natera by 5.0% during the 1st quarter. Earned Wealth Advisors LLC now owns 1,737 shares of the medical research company’s stock valued at $246,000 after acquiring an additional 82 shares during the period. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Insider Buying and Selling

In other news, Director Rowan E. Chapman sold 2,750 shares of the business’s stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $166.99, for a total value of $459,222.50. Following the transaction, the director owned 6,015 shares of the company’s stock, valued at approximately $1,004,444.85. The trade was a 31.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Michael Burkes Brophy sold 3,045 shares of the company’s stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $137.40, for a total transaction of $418,383.00. Following the transaction, the chief financial officer owned 65,430 shares of the company’s stock, valued at approximately $8,990,082. The trade was a 4.45% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 72,464 shares of company stock worth $10,963,125. Corporate insiders own 5.63% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Stephens restated an “overweight” rating and issued a $183.00 price objective on shares of Natera in a report on Friday, August 15th. Royal Bank Of Canada set a $268.00 price target on shares of Natera and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. Cowen reaffirmed a “buy” rating on shares of Natera in a research report on Friday, August 8th. Piper Sandler reiterated an “overweight” rating and issued a $220.00 target price (up from $210.00) on shares of Natera in a report on Monday, August 11th. Finally, Morgan Stanley reissued an “overweight” rating and set a $195.00 target price on shares of Natera in a research note on Sunday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Natera has an average rating of “Moderate Buy” and an average target price of $192.88.

Natera Trading Up 4.5%

NTRA stock opened at $167.35 on Monday. The company has a market capitalization of $22.97 billion, a P/E ratio of -87.62 and a beta of 1.74. The business has a 50 day simple moving average of $161.17 and a 200-day simple moving average of $156.66. Natera, Inc. has a twelve month low of $117.27 and a twelve month high of $183.00.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Thursday, August 7th. The medical research company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The business had revenue of $546.60 million during the quarter, compared to analysts’ expectations of $476.84 million. During the same quarter last year, the company earned ($0.30) EPS. The firm’s revenue for the quarter was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. Research analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.